ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Cardiol Therapeutics Inc

Cardiol Therapeutics Inc (CRDL)

1.80
-0.02
(-1.10%)
Closed March 27 04:00PM
1.80
0.00
( 0.00% )
Pre Market: 04:22AM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

CRDL News

Official News Only

CRDL Discussion

View Posts
Monksdream Monksdream 4 days ago
CRDL 10Q due 3/26
Next day settlement 5/28 per SEC mandate
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 4 weeks ago
CRDL...MONSTER BREAK OUT!
๐Ÿ‘๏ธ0
Sirpeter Sirpeter 4 weeks ago
Taking names and kicking ass...
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 4 weeks ago
CRDL..HERES 2 BUCKS...MASTER CALLS THE BIGGEST PLAYS ON THE INTERNET.!!
๐Ÿ‘๏ธ0
Sirpeter Sirpeter 4 weeks ago
Next push.. ready to go
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 4 weeks ago
CRDL...READY TO BREAK 2 BUCKS...WHAT A CALL....
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 4 weeks ago
CRDL monster move here, another magical trend call!
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 weeks ago
I think Investors Hub has resolved the hack
๐Ÿ‘๏ธ0
Sirpeter Sirpeter 4 weeks ago
Monster play ahead...
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 weeks ago
CRDL new 52 week high
๐Ÿ‘๏ธ0
Sirpeter Sirpeter 1 month ago
Good call boss...moving up
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
CRDL////BREAK OUT
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 month ago
CRDL...............................................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Sirpeter Sirpeter 1 month ago
Added
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
CRDL....BLASTING UP
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
CRDL...CLEAN 1.62 BREAK OUT!!!
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 1 month ago
CRDL...BREAK OUT ON THE WEEKLY....VERY NICE
๐Ÿ‘๏ธ0
subslover subslover 1 month ago
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Newsfile Corp.
Newsfile Corp
Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II Study

This is a Designated News Release.

Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") for the Company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis.

"The FDA's decision was based on pre-clinical data combined with initial clinical data from the Company's MAvERIC-Pilot Phase II study," commented Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. "This designation reinforces the potential of CardiolRx™ to improve the lives of patients suffering with recurrent pericarditis, a debilitating heart disease associated with symptoms that adversely affect quality of life and physical activity."

The FDA grants ODD to a drug or biological product to prevent, diagnose, or treat a rare disease or conditions that affect fewer than 200,000 people in the United States. ODD provides benefits to sponsors including potential seven-year marketing exclusivity, exemptions from certain FDA fees, and tax credits for qualified clinical trials. Products with ODD may also qualify for accelerated regulatory review via Fast Track, Breakthrough Therapy, or Priority Review designations.

MAvERIC-Pilot (NCT05494788) is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis. In addition to standard safety assessments, MAvERIC-Pilot is designed to evaluate improvement in objective measures of this rare disease. The primary efficacy endpoint is the change, from baseline to eight weeks, in patient-reported pericarditis pain using an 11-point numeric rating scale ("NRS"). The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis. Secondary endpoints include the NRS score after 26 weeks of treatment, and changes in circulating levels of C-reactive protein, a commonly used clinical marker of inflammation. Importantly, the study will assess freedom from pericarditis recurrence.

Recurrent pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart) that follows an initial episode (frequently resulting from a viral infection). Patients may have multiple recurrences. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Significant accumulation of pericardial fluid and scarring can progress to life-threatening constriction of the heart. The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention. On an annual basis, the number of patients in the United States having experienced at least one recurrence is estimated at 38,000. Approximately 60% of patients with multiple recurrences (>1) still suffer for longer than 2 years, and one third are still impacted at 5 years. Hospitalization due to recurrent pericarditis is often associated with a 6-8-day length of stay and cost per stay is estimated to range between $20,000 and $30,000 in the United States.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the FDA to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study; NCT05494788), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fati
๐Ÿ‘๏ธ0
Billy75 Billy75 4 months ago
Wife just saw this company today in Sarasota area for luncheon. What is the deal with them? They are going NASDAQ so Iโ€™m assuming they have to get this to $5 a share, right?
๐Ÿ‘๏ธ0
12yearplan 12yearplan 12 months ago
Market seems to have liked the update today:
https://stockhouse.com/news/press-releases/2023/03/29/cardiol-therapeutics-announces-year-end-2022-update-on-operations
๐Ÿ‘๏ธ0
12yearplan 12yearplan 1 year ago
๐Ÿ‘๏ธ0
12yearplan 12yearplan 1 year ago
Filings says it all - lean and mean:
https://www.sec.gov/Archives/edgar/data/1702123/000110465922117212/tm2227599d1_ex99-1.htm
https://quantisnow.com/insight/3668667
$CRDL
๐Ÿ‘๏ธ0
12yearplan 12yearplan 1 year ago
Yes, screamin' buy at historical lows..
๐Ÿ‘๏ธ0
Porterhouse10 Porterhouse10 1 year ago
Share price says it all $CRDL
๐Ÿ‘๏ธ0
12yearplan 12yearplan 1 year ago
Don't know Porter. Looks like the market is likin' the news today and why not I suppose - drugs seem to be workin':

https://stockhouse.com/news/press-releases/2022/11/07/cardiol-therapeutics-announces-study-results-demonstrating-protective-effects-of#BBSL20221107
๐Ÿ‘๏ธ0
Porterhouse10 Porterhouse10 2 years ago
Where's Steve Grasso now? Lmao
๐Ÿ‘๏ธ0
Porterhouse10 Porterhouse10 2 years ago
Grasso's I'm an Advisor to $CRDL pumps are working, people shorting his picks now
๐Ÿ‘๏ธ0
12yearplan 12yearplan 2 years ago
Don't lose at this price point historically; always time I suppose ;)
CRDL$
.. takin' away the freedom..
๐Ÿ‘๏ธ0
Porterhouse10 Porterhouse10 2 years ago
Trading sideways a bit here, not a bad sign
๐Ÿ‘๏ธ0
12yearplan 12yearplan 2 years ago
Two low ebbs/double bottom - must be a time of interest.
๐Ÿ‘๏ธ0
Porterhouse10 Porterhouse10 2 years ago
Steve Grasso must be so proud!
๐Ÿ‘๏ธ0
12yearplan 12yearplan 2 years ago
Haven't been following lately but chart looks at low ebb and..


Cardiol Omicron
As Omicron spreads like wildfire and hospitalizations increase, it is highly likely Cardiol Rx will be fast tracked. Retail investors have short memories but this is going to be huge: "High-risk patients with Cardiovascular Disease (CVD), hospitalized with COVID-19 CardiolRx Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease".
๐Ÿ‘๏ธ0
Porterhouse10 Porterhouse10 2 years ago
Looks like another Steve Grasso disappointment, chalk up another
๐Ÿ‘๏ธ0
srloan srloan 3 years ago
Boom time coming soon !!!
๐Ÿ‘๏ธ0
Porterhouse10 Porterhouse10 3 years ago
Steve Grasso
๐Ÿ‘๏ธ0
Renee Renee 3 years ago
CRTPF changed to CRDL. Moved to the Nasdaq from the OTC:


https://www.sec.gov/Archives/edgar/data/1702123/000106299321007173/form6k.htm


https://otce.finra.org/otce/dailyList?viewType=Deletions
๐Ÿ‘๏ธ0
Tiresias Tiresias 3 years ago
Can I undo my seat belt? It has been almost three weeks and the ride has not moved.
๐Ÿ‘๏ธ0
DoctorRutch DoctorRutch 3 years ago
This is very close to turning right around. Buckle up
๐Ÿ‘๏ธ0
Tiresias Tiresias 3 years ago
Really? Watching, so far nothing, no "short squeeze" as you inferred, share price falling. Do you see an influx? If so, can you point it out. When I see pumping on the message board usually the sign to stay away from it for the time being. People trying to get out from the last bump.
๐Ÿ‘๏ธ0
DoctorRutch DoctorRutch 3 years ago
Watch for an influx of buying from houses that were short Cardiol. Itโ€™s to difficult to short this play with a phase II & III going on with expected fantastic results. Easy double from here boys.
๐Ÿ‘๏ธ0
barnyarddog barnyarddog 3 years ago
https://twitter.com/CardiolRx/status/1318516310637187072/photo/1
๐Ÿ‘๏ธ0
barnyarddog barnyarddog 3 years ago
FDA Approves Landmark COVID/Heart/CBD Clinical Trial

September 30, 2020
https://biotechstocktrader.com/fda-approves-landmark-covid-heart-cbd-clinical-trial/
๐Ÿ‘๏ธ0
barnyarddog barnyarddog 3 years ago
September 25, 2020 Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial

Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRxโ„ข in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD)

https://www.cardiolrx.com/cardiol-therapeutics-receives-fda-approval-for-investigational-new-drug-ind-application-for-phase-ii-iii-covid-19-trial/
๐Ÿ‘๏ธ0
barnyarddog barnyarddog 3 years ago
https://www.cardiolrx.com/investors/press-releases/
๐Ÿ‘๏ธ0
barnyarddog barnyarddog 3 years ago
CardiolRx is a cannabidiol formulation being developed for the treatment of inflammatory cardiovascular conditions.

https://www.cardiolrx.com/products/cardiolrx-cbd/
๐Ÿ‘๏ธ0
barnyarddog barnyarddog 3 years ago
Cardiol Therapeuticsโ€™ Cortalexโ„ข CBD Now Available Exclusively Online at Medical Cannabis by Shoppers Inc.

October 20, 2020

https://biotechstocktrader.com/cardiol-therapeutics-cortalex-cbd-now-available-exclusively-online-at-medical-cannabis-by-shoppers-inc/


....The Company recently received approval from the U.S. FDA for its Investigational New Drug (IND) application to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead product, CardiolRxโ„ข, in hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. CardiolRxโ„ข is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC-free (<10 ppm).
๐Ÿ‘๏ธ0
DoctorRutch DoctorRutch 3 years ago
This is heading straight to $7.00 to $8.00 !!!!!!!! Have you guys seen who is involved in the phase 2 and three trials? Do your homework here. This one is a complete no brainer for me and my group. During the second wave, this could bring down the mortality rate. This has global implications and could catapult this company into the global medical spotlight. Buckle up peeps, buckle up!
๐Ÿ‘๏ธ0
Tiresias Tiresias 3 years ago
I am not familiar with REFG. Cardiol is a Canadian company I believe and inter-listed. For full disclosure you can access public company documents through Canada's system for disclosure, like our EDGAR. It is called SEDAR and can be found at sedar.com. You can put the company name in and see the latest disclosure which was October 5 this year. The company filed a material change report related to the FDA testing approval. I would rely upon the SEDAR system for this company rather than OTC filings for this company. The one ad I saw that concerned me was a banner on top of the Ihub page with a big OK stamp-like add stating FDA APPROVED which some might think meant the drug was ok'ed for use when it fact it was approved only for testing, not use. A slight bit of enhancement but one which I dislike immensely because of its inference. Legitimate companies, especially those trading on the OTC hurt themselves when they lower themselves to that type of marketing - it always makes me feel someone is hyping the stock for insider enrichment. Testing can take years so that type of marketing provides an opportunity for pumping.
๐Ÿ‘๏ธ0
I-Man I-Man 3 years ago
This is an OTC stock firstly ! Then I am told Maria Bartiroma mentioned this company yesterday on Fox Business News?? I am very surprised at her doing so, knowing her for decades as I do, and this only an OTC stock. Not a big board stock...??
๐Ÿ‘๏ธ0
I-Man I-Man 3 years ago
So this is another "CBD" MJ type stock still again? Look at REFG to see what's NOT happening out there, as they have/had actual proprietary payment system with meetings with banking commission, etc and yet, their stock crappy for last few years...

๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock